Skip to main content
GlaxoSmithKline PLC logo

GlaxoSmithKline PLC — Investor Relations & Filings

Ticker · GSK ISIN · GB00BN7SWP63 LEI · 5493000HZTVUYLO1D793 IL Manufacturing
Open in API
Filings indexed 7,016 across all filing types
Latest filing 2026-04-01 Director's Dealing
Country GB United Kingdom
Listing IL GSK

About GlaxoSmithKline PLC

https://www.gsk.com/en-gb/

GSK plc is a global biopharmaceutical company that unites science, technology, and talent to research, develop, and manufacture medicines and vaccines. The company focuses on preventing and treating disease across four primary therapeutic areas: infectious diseases, HIV, oncology, and immunology/respiratory. Its portfolio consists of specialty medicines and vaccines aimed at addressing significant global health needs. GSK's strategy centers on leveraging its research and development capabilities to deliver new health solutions.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 95% confidence The document is an RNS announcement detailing insider transactions by a PDMR (Chief People Officer Diana Conrad) acquiring ADS under the company’s pension plan, including dates, volumes, and prices. This matches the definition of a Director’s Dealing report (personal share transactions by company directors/executives).
2026-04-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is an RNS announcement titled “Total Voting Rights,” notifying the market of the company’s issued share capital and voting rights as of 31 March 2026 to comply with FCA Disclosure Guidance and Transparency Rule 5.6.1R. This is not a full report but a voting rights announcement. It fits the category “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-04-01 English
6-K - GSK plc (0001131399) (Filer)
Foreign Filer Report
2026-04-01 English
6-K - GSK plc (0001131399) (Filer)
Foreign Filer Report
2026-04-01 English
ViiV completes changes to minority shareholding
Share Issue/Capital Change Classification · 85% confidence The document is an RNS announcement by GSK plc regarding the completion of a transaction in which ViiV Healthcare issued new shares to Shionogi (and cancelled Pfizer’s holding), thereby changing the capital structure and share ownership percentages. This is not a full annual or interim report, nor an earnings release or management discussion, but a specific notification of a share issuance and cancellation – a capital change. Therefore, it best fits the Share Issue/Capital Change category (SHA).
2026-04-01 English
Transaction in Own Shares
Transaction in Own Shares Classification · 93% confidence The document is an RNS announcement titled “Transaction in own shares,” detailing the number of shares repurchased, dates, prices, and a schedule of individual trades under the company’s buyback programme. It is a report of the company buying back its own shares, matching the definition for Transaction in Own Shares (POS).
2026-04-01 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.